HAR1B

Across TCGA pan-cancer cohorts, HAR1B RNA differs between tumor and matched normal tissue in 8 of 18 cancer types tested, making tumor–normal expression one of HAR1B’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where HAR1B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types HAR1B is over-expressed in tumor, although a few such as UCEC and THCA show the opposite, repressed pattern.

KIRC, UCEC, and BRCA are the cancer types where HAR1B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HAR1B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	All	+0.184	<.001	8	view →
UCEC	All	All	−0.393	<.001	6	view →
BRCA	Female	All	+0.493	<.001	4	view →
THCA	Male	All	−0.207	.006	4	view →
HNSC	All	All	+0.185	.009	4	view →
COAD	Male	II,III,IV	+0.511	.042	2	view →
LUAD	All	All	+0.244	.003	2	view →
PRAD	All	All	−0.193	.001	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 8 strongest of 8 lineages.

HAR1B–KIRC

Open the KIRC breakdown →